EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC

Jiajuan Wu, Jiawei Zhai, Leilei Lv, Yaoxin Zhang, Yu Shen, Qiuxia Qu, Cheng Chen

Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e014940

DOI: 10.1136/jitc-2026-014940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 25.06.2026. Verfasst von Jiajuan Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology Institute, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, CD8-Positive T-Lymphocytes, Apyrase. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Invigorating Health Care through Science, Technology and Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Understanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39) + cluster of differentiation 8 (CD8) + T cells have been associated with antitumor responses, the naïve regional distribution of these cells and their dysregulated dynamics as determinants of response or resistance to anti-PD-1 monoclonal antibody (mAb) therapy remain poorly characterized.

Methods

We employed targeted biopsy techniques to characterize the spatial infiltration of CD39 + CD8 + T cells within the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC). It was further performed independent NSCLC cohort, flow cytometry, multiplex immunohistochemistry, single-cell RNA sequencing and functional studies to investigate these cells in vitro and in vivo.

Results

Region-specific CD39 + CD8 + T cells located outside hypoxic zones initially served as potential biomarkers to predict response to anti-PD-1 therapy. However, hypoxia gradients within the TME were associated with regional depletion of these cells in NSCLC. Subsequently, anti-PD-1 mAb treatment further reduced intratumoral CD39 + CD8 + T-cell levels, even in the context of improved oxygenation following tumor regression, suggesting a feedback mechanism modulating antitumor immunity. Multiple assays revealed that the absence of CD39 impaired functional restoration of CD8 + T cells on PD-1 blockade. This finding was corroborated by distinct transcriptional profiles, enhanced cytotoxic/effector signatures, and a more oligoclonal and expanded T-cell receptor (TCR) repertoire in CD39 + CD8 + T cells across the CD8 + T-cell differentiation continuum.

Conclusions

These findings identify CD39 + CD8 + T cells as an important regulator of anti-PD-1 therapy, whereas initial hypoxia followed by anti-PD-1 treatment sequentially shapes tumor-regional localization of these cells, ultimately linking to suboptimal immunotherapeutic responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCD8-Positive T-LymphocytesApyraseImmune Checkpoint InhibitorsImmunotherapyProgrammed Cell Death 1 ReceptorDrug Resistance, NeoplasmHumansAnimalsMiceTumor MicroenvironmentAntigens, CDFemale

Stichwörter der Autor:innen

ImmunotherapyLung CancerT cellTumor microenvironment - TME

Substanzen

ApyraseImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorENTPD1 protein, humanAntigens, CDCD39 antigenPDCD1 protein, human

Autor:innen und Institutionen

  • Clinical Immunology Institute, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Clinical Laboratory, The First Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.
  • Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Pulmonary and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, China.
  • Department of Pulmonary and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
  • Clinical Immunology Institute, The First Affiliated Hospital of Soochow University, Suzhou, China chencheng@suda.edu.cn qxqu@suda.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Invigorating Health Care through Science, Technology and Education

Zitieren

APA

Wu, J., Zhai, J., Lv, L., Zhang, Y., Shen, Y., Qu, Q., & Chen, C. (2026). Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC. Journal for ImmunoTherapy of Cancer, 14(6), e014940. https://doi.org/10.1136/jitc-2026-014940

Vancouver

Wu J, Zhai J, Lv L, Zhang Y, Shen Y, Qu Q, et al. Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC. Journal for ImmunoTherapy of Cancer. 2026;14(6):e014940. doi:10.1136/jitc-2026-014940

BibTeX
@article{Wu2026,
  author = {Wu, Jiajuan and Zhai, Jiawei and Lv, Leilei and Zhang, Yaoxin and Shen, Yu and Qu, Qiuxia and Chen, Cheng},
  title = {Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {e014940},
  doi = {10.1136/jitc-2026-014940}
}
Kostenlos starten →